In:
Pancreas, Ovid Technologies (Wolters Kluwer Health), Vol. 49, No. 10 ( 2020-11), p. 1348-1354
Abstract:
The association of Lewis antigen phenotype with survival of patients with pancreatic ductal adenocarcinoma was investigated. Methods A total of 1187 patients diagnosed with pancreatic ductal adenocarcinoma were evaluated in a prospective cohort. Patients were classified into 3 different groups according to Lewis antigen phenotype: Lewis antigen (1) A positive [Le(a+b−)], (2) B positive [Le(a−b+)] , and (3) negative [Le(a−b−)]. Risk of mortality was analyzed with Cox regression after adjusting for other predictors. Results The risk of mortality increased in the order of Le(a+b−), Le(a−b+), and Le(a−b−) [reference; hazard ratio (HR), 1.27; 95% confidence interval (CI)], 1.03–1.57; P = 0.02; and HR, 1.65; 95% CI, 1.31–2.09; P 〈 0.001] after adjusting for other predictors. Among patients with serum carbohydrate antigen (CA) 19-9 lower than 37 U/mL, the association seemed more apparent (reference; HR, 1.50; 95% CI, 0.77–2.29; P = 0.22; and HR, 2.10; 95% CI, 1.10–4.02; P 〈 0.02). Conclusions The risk of mortality increased in the order of Le(a+b−), Le(a−b+), and Le(a−b−). The difference in prognosis according to the Lewis antigen phenotype was more pronounced in the low CA 19-9 group, which suggests that the Lewis antigen phenotype works as a biomarker predicting the prognosis of patients with pancreatic cancer with undetectable CA 19-9 level.
Type of Medium:
Online Resource
ISSN:
1536-4828
,
0885-3177
DOI:
10.1097/MPA.0000000000001687
Language:
English
Publisher:
Ovid Technologies (Wolters Kluwer Health)
Publication Date:
2020
detail.hit.zdb_id:
2053902-2
Permalink